Announcements Trials
Browse Landscape

Phase

Phase 3 10Phase 2 4Phase 1 3

Status

Completed 4

Sponsor Class

OTHER 21INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Leiomyoma 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × relugolix × Clear all
NCT04523207 2026-04-21

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Janssen Research & Development, LLC

Phase 2 Completed
108 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT02083185 2018-05-09

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Takeda

Phase 2 Completed
136 enrolled 26 charts
Genitourinary

Prostatic Neoplasms

NCT02135445 2017-04-13

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Takeda

Phase 2 Completed
103 enrolled 42 charts
Genitourinary

Prostatic Neoplasms

NCT01452659 2013-01-21

Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids

Takeda

Phase 2 Completed
216 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡